Bookmarks
CCU077: Risk assessment and long-term outcomes of acute coronary syndrome management strategy in cardio-oncology patients before and after the COVID era
Safe People
Organisation name
University College London
Organisation sector
3
Applicant name(s)
Mohamed Mohamed
Ami Banerjee
Funders/ Sponsors
Safe Projects
Project ID
CCU077
Lay summary
Cancer patients are at a heightened risk of heart attacks, formally known as acute coronary syndrome (ACS). Whilst the gold standard therapy for ACS is percutaneous coronary intervention (PCI), using a stent to open narrowed or blocked arteries, for reduction in cardiovascular mortality and morbidity. There is a caution among cardiologists when offering this treatment to cancer patients due to their high bleeding risk, which could be equally fatal. My previous work has suggested that PCI in cancer patients presenting with heart attacks is associated with reduced in-hospital deaths without an added risk of major bleeding. However, most bleeding events after ACS occur post-discharge. It is, therefore, unclear whether the benefits of PCI outweigh the risk of major bleeding in this high-risk population that is frequently under-represented in trials. Furthermore, the COVID-19 pandemic has had a significant impact on the care for cancer patients especially in the context of ACS. Therefore, an understanding of how cancer patients presenting with ACS were managed (conservative vs. PCI) during and after the COVID-19 pandemic is essential. The proposed project aims to retrospectively analyse national electronic health record data to systematically examine and compare longer-term outcomes (at 30-days and 1-year) of cancer patients presenting with heart attacks (ACS) who undergo PCI (stents) or medical management with blood thinning medications (antiplatelet therapy) alone, including heart-related deaths (cardiac mortality) and recurrent heart attacks (reinfarction), major bleeding, and hospital readmissions over three time periods: pre-COVID (before March 2020), COVID (March 2022-April 2022) and post-COVID (April 2022 onwards). Furthermore, this project will assess the performance of traditional ACS risk scores (GRACE and CRUSADE) for predicting mortality and major bleeding, respectively, in the cancer population.
Public benefit statement
The findings from this work are expected to have important clinical implications by providing cardiologists and oncologists (cancer specialists) with valuable outcomes data to guide their clinical decisions when managing this high-risk and increasingly encountered population. It will also build the case for prospective work on the recalibration of existing risk scores to incorporate cancer as part of the risk prediction models and, therefore, improve the risk assessment of this underrepresented population. Visit the BHF Data Science Centre website for more detailed information about project outputs. https://bhfdatasciencecentre.org/projects/ccu077/
Technical summary
This project accessed the following datasets within the Trusted Research Environment(s) for CVD-COVID-UK / COVID-IMPACT: - ENGLAND: - Civil Registration - Deaths - Emergency Care Data Set (ECDS) - GPES Data for Pandemic Planning and Research (COVID-19) - Hospital Episode Statistics Admitted Patient Care - NICOR – MINAP: Myocardial Ischaemia National Audit Project - NICOR – NACSA: National Adult Cardiac Surgery Audit - NICOR – PCI: Percutaneous Coronary Interventions - Secondary Uses Services Payment By Results
Other approval committees
Project start date
03/12/2023
Project end date
03/12/2024
Latest approval date
01/05/2024
Safe Data
Dataset(s) name
Data sensitivity level
De-Personalised
Release/Access date
01/05/2024
Safe Setting
Access type
TRE